XML 78 R46.htm IDEA: XBRL DOCUMENT
v3.19.1

Revenues Revenues by Product (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2019 | Mar. 31, 2018
Disaggregation of Revenue [Line Items] |  |
Product revenues | $ 3,489.8 | $ 3,131.1
TECFIDERA |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 998.8 | 986.9
TECFIDERA | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 717.7 | 728.9
TECFIDERA | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 281.1 | 258.0
Interferon |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 500.9 | 550.3
Interferon | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 327.3 | 371.4
Interferon | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 173.6 | 178.9
TYSABRI |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 460.4 | 462.1
TYSABRI | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 245.0 | 249.7
TYSABRI | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 215.4 | 212.4
FAMPYRA |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 22.9 | 24.4
FAMPYRA | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 0.0 | 0.0
FAMPYRA | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 22.9 | 24.4
ZINBRYTA |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 0.0 | 1.4
ZINBRYTA | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 0.0 | 0.0
ZINBRYTA | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 0.0 | 1.4
MS Product Revenues |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 1,983.0 | 2,025.1
MS Product Revenues | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 1,290.0 | 1,350.0
MS Product Revenues | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 693.0 | 675.1
SPINRAZA |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 518.5 | 363.9
SPINRAZA | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 223.3 | 188.0
SPINRAZA | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 295.2 | 175.9
BENEPALI |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 124.0 | 120.9
BENEPALI | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 0.0 | 0.0
BENEPALI | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 124.0 | 120.9
FLIXABI |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 14.7 | 6.6
FLIXABI | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 0.0 | 0.0
FLIXABI | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 14.7 | 6.6
IMRALDI |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 35.7 | 0.0
IMRALDI | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 0.0 | 0.0
IMRALDI | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 35.7 | 0.0
Biosimilars |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 174.4 | 127.5
Biosimilars | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 0.0 | 0.0
Biosimilars | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 174.4 | 127.5
FUMADERM |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 4.1 | 7.0
FUMADERM | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 0.0 | 0.0
FUMADERM | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 4.1 | 7.0
Product, net |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 2,680.0 | 2,523.5
Product, net | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | 1,513.3 | 1,538.0
Product, net | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Product revenues | $ 1,166.7 | $ 985.5

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=biib_TecfideraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_InterferonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_TysabriProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_FAMPYRAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_ZINBRYTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_MSProductRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_SPINRAZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_BENEPALIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_FLIXABIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_IMRALDIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_BiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_FUMADERMMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |